

**TDMS No.** 99024 - 08  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Androstenedione  
**CAS Number:** 63-05-8

**Date Report Requested:** 05/09/2008  
**Time Report Requested:** 12:55:58  
**First Dose M/F:** 12/16/02 / 12/16/02  
**Lab:** SRI

F1\_M3

**C Number:** C99024C  
**Lock Date:** 06/29/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	5	2	5	3
Natural Death	9	4	11	10
Survivors				
Terminal Sacrifice	36	44	34	37
Animals Examined Microscopically	50	50	50	50

**ALIMENTARY SYSTEM**

Gallbladder	(45)	(46)	(42)	(44)
Epithelium, Cytoplasmic Alteration		1 (2%)		
Intestine Large, Cecum	(50)	(49)	(50)	(49)
Edema	1 (2%)	1 (2%)	1 (2%)	
Intestine Small, Duodenum	(47)	(49)	(46)	(49)
Intestine Small, Ileum	(49)	(50)	(49)	(49)
Hyperplasia, Lymphoid	1 (2%)			
Intestine Small, Jejunum	(47)	(49)	(47)	(49)
Hyperplasia, Lymphoid	1 (2%)		1 (2%)	1 (2%)
Epithelium, Hyperplasia		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Basophilic Focus	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Clear Cell Focus	27 (54%)	24 (48%)	18 (36%)	12 (24%)
Cyst	1 (2%)			2 (4%)
Eosinophilic Focus	13 (26%)	10 (20%)	11 (22%)	25 (50%)
Hematopoietic Cell Proliferation		1 (2%)	4 (8%)	
Hemorrhage	1 (2%)	1 (2%)		1 (2%)
Infiltration Cellular			2 (4%)	
Infiltration Cellular, Mixed Cell	1 (2%)	1 (2%)	5 (10%)	2 (4%)
Mitotic Alteration			1 (2%)	
Mixed Cell Focus	10 (20%)	10 (20%)	11 (22%)	13 (26%)
Necrosis				1 (2%)
Necrosis, Focal	3 (6%)	3 (6%)	5 (10%)	6 (12%)
Tension Lipidosis				1 (2%)
Vacuolization Cytoplasmic	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Centriobular, Necrosis	2 (4%)		3 (6%)	4 (8%)
Hepatocyte, Vacuolization Cytoplasmic	17 (34%)	14 (28%)	14 (28%)	12 (24%)
Kupffer Cell, Hyperplasia	1 (2%)		1 (2%)	
Mesentery	(5)	(8)	(4)	(5)
Hemorrhage	2 (40%)			

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Fat, Necrosis	4 (80%)	7 (88%)	2 (50%)	4 (80%)
Pancreas	(50)	(50)	(50)	(49)
Atrophy	1 (2%)	2 (4%)		
Thrombosis				1 (2%)
Acinus, Cytoplasmic Alteration	1 (2%)	3 (6%)	2 (4%)	
Acinus, Hyperplasia, Focal	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy	1 (2%)			1 (2%)
Infiltration Cellular, Lymphocyte	2 (4%)	4 (8%)	3 (6%)	6 (12%)
Stomach, Forestomach	(49)	(50)	(50)	(50)
Edema				1 (2%)
Erosion	1 (2%)			
Inflammation, Chronic		1 (2%)		1 (2%)
Ulcer	1 (2%)	1 (2%)	1 (2%)	
Epithelium, Hyperplasia	1 (2%)	5 (10%)	1 (2%)	2 (4%)
Stomach, Glandular	(49)	(50)	(50)	(50)
Edema			1 (2%)	
Erosion			2 (4%)	1 (2%)
Epithelium, Hyperplasia	1 (2%)	2 (4%)		
Epithelium, Hyperplasia, Focal	1 (2%)			
Tooth	(0)	(1)	(0)	(0)
<b>CARDIOVASCULAR SYSTEM</b>				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	4 (8%)	4 (8%)	5 (10%)	7 (14%)
Hemorrhage				1 (2%)
Inflammation, Chronic			1 (2%)	
Mineralization			1 (2%)	
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	6 (12%)	1 (2%)	3 (6%)	2 (4%)
Hyperplasia, Focal	4 (8%)	5 (10%)	5 (10%)	3 (6%)
Hypertrophy, Focal	10 (20%)	7 (14%)	11 (22%)	9 (18%)
Metaplasia, Osseous	1 (2%)			
Capsule, Hyperplasia	5 (10%)	4 (8%)	5 (10%)	10 (20%)
Adrenal Medulla	(49)	(49)	(50)	(50)
Hyperplasia			1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(49)
Hyperplasia	12 (24%)	14 (28%)	11 (22%)	6 (12%)
Parathyroid Gland	(48)	(48)	(47)	(46)
Cyst	1 (2%)			1 (2%)

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Pituitary Gland	(50)	(49)	(49)	(50)
Pars Distalis, Cyst	4 (8%)	2 (4%)	4 (8%)	3 (6%)
Pars Distalis, Hyperplasia, Focal	1 (2%)			1 (2%)
Thyroid Gland	(50)	(50)	(50)	(50)
Follicle, Cyst				1 (2%)
Follicle, Degeneration, Focal	12 (24%)	8 (16%)	9 (18%)	9 (18%)
Follicular Cell, Hyperplasia				2 (4%)
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
Epididymis	(50)	(50)	(50)	(50)
Granuloma Sperm	1 (2%)			
Spermatocele	1 (2%)			
Preputial Gland	(50)	(50)	(50)	(50)
Cyst	1 (2%)	2 (4%)		4 (8%)
Inflammation, Chronic	7 (14%)	4 (8%)	3 (6%)	7 (14%)
Prostate	(50)	(50)	(50)	(50)
Inflammation, Chronic	3 (6%)			
Seminal Vesicle	(50)	(50)	(50)	(50)
Degeneration		1 (2%)		
Inflammation, Chronic	1 (2%)			1 (2%)
Testes	(50)	(50)	(50)	(50)
Germinal Epithelium, Atrophy	2 (4%)	2 (4%)	4 (8%)	2 (4%)
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Hyperplasia	19 (38%)	30 (60%)	23 (46%)	30 (60%)
Infiltration Cellular, Histiocyte			1 (2%)	
Myelofibrosis			1 (2%)	
Lymph Node	(2)	(1)	(1)	(4)
Iliac, Hyperplasia, Lymphoid			1 (100%)	
Lymph Node, Mandibular	(47)	(47)	(47)	(47)
Atrophy			3 (6%)	
Hematopoietic Cell Proliferation	1 (2%)	1 (2%)		
Hyperplasia, Lymphoid	5 (11%)	5 (11%)	3 (6%)	3 (6%)
Pigmentation	1 (2%)			1 (2%)
Lymph Node, Mesenteric	(49)	(49)	(49)	(45)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Angiectasis			2 (4%)	
Atrophy		4 (8%)	6 (12%)	
Hematopoietic Cell Proliferation	4 (8%)	4 (8%)	6 (12%)	2 (4%)
Hemorrhage	4 (8%)	4 (8%)	7 (14%)	2 (4%)
Hyperplasia, Lymphoid	2 (4%)	5 (10%)	1 (2%)	4 (9%)
Spleen	(50)	(50)	(50)	(50)
Accessory Spleen	1 (2%)	1 (2%)		
Fibrosis	1 (2%)			
Hematopoietic Cell Proliferation	23 (46%)	25 (50%)	28 (56%)	28 (56%)
Necrosis				1 (2%)
Lymphoid Follicle, Atrophy		1 (2%)	4 (8%)	
Lymphoid Follicle, Hyperplasia		1 (2%)	1 (2%)	1 (2%)
Thymus	(45)	(46)	(42)	(45)
Atrophy	4 (9%)	5 (11%)	13 (31%)	8 (18%)
Cyst		2 (4%)		5 (11%)
Hyperplasia, Lymphoid		2 (4%)	1 (2%)	
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion			1 (2%)	
Edema	1 (2%)	1 (2%)	1 (2%)	
Hemorrhage	1 (2%)			
Hyperkeratosis	1 (2%)			
Ulcer		2 (4%)		1 (2%)
Epidermis, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Cranium, Osteopetrosis			1 (2%)	2 (4%)
Skeletal Muscle	(1)	(1)	(2)	(1)
Atrophy			1 (50%)	1 (100%)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(49)	(50)
Cyst Epithelial Inclusion		1 (2%)		
Hemorrhage	1 (2%)	1 (2%)		
Peripheral Nerve	(1)	(1)	(4)	(3)
Atrophy		1 (100%)	2 (50%)	1 (33%)
Spinal Cord	(1)	(1)	(4)	(3)
Necrosis			1 (25%)	

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Foreign Body			1 (2%)	
Hemorrhage	4 (8%)	1 (2%)	1 (2%)	2 (4%)
Infiltration Cellular, Histiocyte	10 (20%)	5 (10%)	5 (10%)	11 (22%)
Infiltration Cellular, Lymphocyte				1 (2%)
Inflammation, Chronic	1 (2%)			
Metaplasia, Osseous		1 (2%)		
Thrombosis	2 (4%)		1 (2%)	
Alveolar Epithelium, Hyperplasia	4 (8%)	2 (4%)	2 (4%)	3 (6%)
Bronchus, Hyperplasia				1 (2%)
Nose	(50)	(49)	(49)	(50)
Foreign Body	4 (8%)			
Hemorrhage		1 (2%)		
Inflammation, Chronic	5 (10%)	4 (8%)	4 (8%)	3 (6%)
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Atrophy		1 (2%)		
Cataract	1 (2%)	1 (2%)		1 (2%)
Hemorrhage	1 (2%)			
Inflammation, Chronic	3 (6%)	1 (2%)	2 (4%)	
Cornea, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
Retina, Degeneration	1 (2%)			1 (2%)
Harderian Gland	(50)	(50)	(50)	(50)
Cyst			1 (2%)	
Lacrimal Gland	(0)	(1)	(0)	(0)
Duct, Inflammation, Suppurative		1 (100%)		
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Cyst	9 (18%)	16 (32%)	9 (18%)	13 (26%)
Hydronephrosis	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Infarct	4 (8%)	2 (4%)	1 (2%)	5 (10%)
Infiltration Cellular, Lymphocyte	5 (10%)	2 (4%)	4 (8%)	5 (10%)
Inflammation, Suppurative			1 (2%)	
Metaplasia, Osseous	4 (8%)	2 (4%)	5 (10%)	4 (8%)
Mineralization			2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99024 - 08

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

CAS Number: 63-05-8

Date Report Requested: 05/09/2008

Time Report Requested: 12:55:58

First Dose M/F: 12/16/02 / 12/16/02

Lab: SRI

---

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Nephropathy	38 (76%)	45 (90%)	38 (76%)	44 (88%)
Renal Tubule, Accumulation, Hyaline Droplet			1 (2%)	
Renal Tubule, Dilatation, Diffuse			1 (2%)	
Renal Tubule, Hyperplasia	7 (14%)	6 (12%)	6 (12%)	2 (4%)
Renal Tubule, Pigmentation	1 (2%)	3 (6%)	6 (12%)	3 (6%)
Transitional Epithelium, Hyperplasia		1 (2%)		
Urinary Bladder	(50)	(50)	(50)	(50)
Edema	1 (2%)	1 (2%)		
Transitional Epithelium, Hyperplasia		1 (2%)	2 (4%)	

---

\*\*\* END OF MALE \*\*\*

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed	2		1	1
Moribund Sacrifice	6	2	3	3
Natural Death	7	8	6	6
Survivors				
Natural Death	1		1	
Terminal Sacrifice	34	40	39	40
Animals Examined Microscopically	50	50	50	50

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(49)	(50)
Gallbladder	(44)	(45)	(42)	(48)
Cyst				1 (2%)
Intestine Large, Cecum	(49)	(50)	(50)	(49)
Edema		1 (2%)		
Intestine Small, Duodenum	(47)	(46)	(46)	(49)
Metaplasia	1 (2%)			
Epithelium, Hyperplasia			1 (2%)	
Intestine Small, Ileum	(46)	(48)	(49)	(50)
Epithelium, Hyperplasia		1 (2%)		
Intestine Small, Jejunum	(46)	(48)	(49)	(50)
Hyperplasia, Lymphoid		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	1 (2%)	1 (2%)	
Basophilic Focus		4 (8%)	3 (6%)	
Clear Cell Focus	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Eosinophilic Focus	9 (18%)	8 (16%)	11 (22%)	11 (22%)
Hematopoietic Cell Proliferation	6 (12%)	2 (4%)	4 (8%)	3 (6%)
Hemorrhage		1 (2%)		
Infiltration Cellular, Lymphocyte	1 (2%)	2 (4%)	2 (4%)	
Infiltration Cellular, Mixed Cell	2 (4%)	4 (8%)	2 (4%)	
Mixed Cell Focus	2 (4%)	5 (10%)	7 (14%)	15 (30%)
Necrosis, Focal	2 (4%)	5 (10%)	2 (4%)	2 (4%)
Tension Lipidosis	1 (2%)		1 (2%)	2 (4%)
Centriobular, Necrosis	1 (2%)	1 (2%)	1 (2%)	
Hepatocyte, Hypertrophy				1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	6 (12%)	3 (6%)	9 (18%)	22 (44%)
Kupffer Cell, Hyperplasia		1 (2%)	1 (2%)	
Kupffer Cell, Pigmentation	2 (4%)			



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Oval Cell, Hyperplasia				1 (2%)
Mesentery	(7)	(9)	(14)	(8)
Fat, Necrosis	7 (100%)	6 (67%)	13 (93%)	8 (100%)
Oral Mucosa	(0)	(0)	(0)	(1)
Pancreas	(49)	(50)	(50)	(49)
Atrophy	1 (2%)		2 (4%)	4 (8%)
Cyst		1 (2%)	3 (6%)	1 (2%)
Infiltration Cellular, Lymphocyte	1 (2%)			
Acinus, Cytoplasmic Alteration	1 (2%)	1 (2%)	3 (6%)	1 (2%)
Salivary Glands	(49)	(49)	(49)	(50)
Atrophy	1 (2%)			
Infiltration Cellular, Lymphocyte	10 (20%)	12 (24%)	2 (4%)	7 (14%)
Submandibular Gland, Cytoplasmic Alteration		17 (35%)	40 (82%)	45 (90%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Diverticulum		1 (2%)		
Metaplasia, Hepatocyte		1 (2%)		
Ulcer	1 (2%)			1 (2%)
Epithelium, Hyperplasia		1 (2%)	1 (2%)	3 (6%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst	2 (4%)			
Erosion	1 (2%)	1 (2%)		
Metaplasia, Hepatocyte				1 (2%)
Mineralization			1 (2%)	
Ulcer	1 (2%)			
Epithelium, Hyperplasia	1 (2%)			1 (2%)
<b>CARDIOVASCULAR SYSTEM</b>				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	1 (2%)	2 (4%)		2 (4%)
Inflammation, Acute	1 (2%)			
Inflammation, Chronic				1 (2%)
Mineralization	1 (2%)	1 (2%)		
Thrombosis			1 (2%)	
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	3 (6%)	7 (14%)	5 (10%)	3 (6%)
Hyperplasia, Focal	1 (2%)	1 (2%)		1 (2%)
Hypertrophy, Focal		1 (2%)		1 (2%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	4 (8%)	1 (2%)	1 (2%)	1 (2%)
Islets, Pancreatic	(49)	(50)	(49)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Parathyroid Gland	(48)	(49)	(45)	(50)
Cyst		1 (2%)	1 (2%)	2 (4%)
Pituitary Gland	(49)	(47)	(50)	(50)
Pars Distalis, Angiectasis	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Pars Distalis, Cyst	1 (2%)	1 (2%)		1 (2%)
Pars Distalis, Hyperplasia		1 (2%)	1 (2%)	
Pars Distalis, Hyperplasia, Focal	5 (10%)	8 (17%)	7 (14%)	7 (14%)
Thyroid Gland	(50)	(50)	(48)	(50)
Follicle, Cyst			1 (2%)	
Follicle, Degeneration, Focal	26 (52%)	18 (36%)	20 (42%)	19 (38%)
Follicular Cell, Hyperplasia		1 (2%)	2 (4%)	1 (2%)
<b>GENERAL BODY SYSTEM</b>				
Tissue NOS	(1)	(0)	(0)	(1)
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(47)	(47)	(49)	(50)
Hyperplasia		2 (4%)	13 (27%)	41 (82%)
Duct, Dilatation		2 (4%)	17 (35%)	49 (98%)
Ovary	(49)	(50)	(49)	(48)
Angiectasis		4 (8%)	2 (4%)	1 (2%)
Cyst	11 (22%)	14 (28%)	10 (20%)	15 (31%)
Hemorrhage	4 (8%)		1 (2%)	6 (13%)
Corpus Luteum, Hyperplasia		1 (2%)		
Interstitial Cell, Hyperplasia	1 (2%)		2 (4%)	
Uterus	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)		2 (4%)	4 (8%)
Hyperplasia, Cystic	44 (88%)	42 (84%)	42 (84%)	36 (72%)
Endometrium, Dysplasia			1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(49)	(50)	(50)
Hyperplasia	14 (28%)	18 (37%)	23 (46%)	11 (22%)
Infiltration Cellular, Histiocyte			1 (2%)	
Lymph Node	(10)	(5)	(4)	(1)
Iliac, Hematopoietic Cell Proliferation		2 (40%)		
Iliac, Hemorrhage	1 (10%)	1 (20%)		
Iliac, Hyperplasia, Lymphoid		1 (20%)		
Inguinal, Hyperplasia, Lymphoid	1 (10%)			

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Mediastinal, Hyperplasia, Lymphoid			1 (25%)	
Renal, Hematopoietic Cell Proliferation		1 (20%)		
Renal, Hyperplasia, Lymphoid				1 (100%)
Lymph Node, Mandibular	(46)	(49)	(47)	(49)
Atrophy			1 (2%)	
Hematopoietic Cell Proliferation		1 (2%)		1 (2%)
Hemorrhage			2 (4%)	
Hyperplasia, Lymphoid	4 (9%)	3 (6%)	4 (9%)	2 (4%)
Pigmentation	4 (9%)	4 (8%)	4 (9%)	3 (6%)
Lymph Node, Mesenteric	(50)	(50)	(46)	(48)
Atrophy	1 (2%)	1 (2%)	2 (4%)	
Hematopoietic Cell Proliferation			1 (2%)	
Hemorrhage	1 (2%)	4 (8%)	2 (4%)	1 (2%)
Hyperplasia, Lymphoid		3 (6%)	5 (11%)	1 (2%)
Spleen	(50)	(50)	(50)	(50)
Accessory Spleen	1 (2%)			1 (2%)
Hematopoietic Cell Proliferation	28 (56%)	29 (58%)	32 (64%)	22 (44%)
Necrosis	1 (2%)	1 (2%)		
Lymphoid Follicle, Atrophy			1 (2%)	2 (4%)
Lymphoid Follicle, Hyperplasia	7 (14%)	6 (12%)	15 (30%)	8 (16%)
Red Pulp, Hyperplasia				1 (2%)
Thymus	(47)	(46)	(46)	(46)
Atrophy	2 (4%)	3 (7%)	4 (9%)	3 (7%)
Cyst	1 (2%)			
Hyperplasia, Lymphoid		2 (4%)		
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	4 (8%)	3 (6%)	5 (10%)	2 (4%)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion			1 (2%)	
Edema	1 (2%)	1 (2%)		
Inflammation, Chronic	1 (2%)			
Metaplasia, Osseous	1 (2%)			
Ulcer	2 (4%)		2 (4%)	
Epidermis, Hyperplasia	1 (2%)			
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Fibrosis	3 (6%)	4 (8%)	4 (8%)	5 (10%)
Hyperostosis	1 (2%)			
Skeletal Muscle	(4)	(0)	(4)	(2)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Atrophy Hemorrhage			1 (25%)	1 (50%)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(49)	(50)	(50)
Compression			1 (2%)	2 (4%)
Cyst Epithelial Inclusion	1 (2%)			
Gliosis	1 (2%)			1 (2%)
Hydrocephalus				1 (2%)
Peripheral Nerve	(2)	(1)	(3)	(1)
Atrophy	2 (100%)		2 (67%)	1 (100%)
Inflammation, Chronic Active				1 (100%)
Spinal Cord	(2)	(1)	(4)	(1)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Hemorrhage	2 (4%)	3 (6%)	3 (6%)	7 (14%)
Infiltration Cellular, Histiocyte	2 (4%)	1 (2%)	1 (2%)	4 (8%)
Infiltration Cellular, Lymphocyte	1 (2%)	1 (2%)		
Metaplasia, Osseous		1 (2%)		
Mineralization			1 (2%)	
Thrombosis			1 (2%)	
Alveolar Epithelium, Hyperplasia	1 (2%)		1 (2%)	
Nose	(50)	(49)	(50)	(50)
Inflammation, Chronic	1 (2%)	3 (6%)		4 (8%)
Trachea	(50)	(50)	(48)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(50)	(50)
Cataract			2 (4%)	
Inflammation, Chronic	2 (4%)		2 (4%)	1 (2%)
Cornea, Hyperplasia	2 (4%)		1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia, Focal	1 (2%)	2 (4%)	1 (2%)	1 (2%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Cyst		1 (2%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Glomerulosclerosis			3 (6%)	
Hydronephrosis				1 (2%)
Infarct	4 (8%)	3 (6%)	1 (2%)	
Infiltration Cellular, Lymphocyte	4 (8%)	4 (8%)	2 (4%)	3 (6%)
Inflammation, Suppurative	2 (4%)		1 (2%)	
Metaplasia, Osseous	1 (2%)	2 (4%)		3 (6%)
Nephropathy	13 (26%)	11 (22%)	13 (26%)	14 (28%)
Glomerulus, Metaplasia	2 (4%)	1 (2%)	5 (10%)	27 (54%)
Renal Tubule, Accumulation, Hyaline Droplet	1 (2%)	3 (6%)		
Renal Tubule, Hyperplasia		1 (2%)		1 (2%)
Renal Tubule, Pigmentation		1 (2%)		1 (2%)
Transitional Epithelium, Hyperplasia			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte	1 (2%)	4 (8%)	2 (4%)	
Inflammation, Chronic	1 (2%)			
Transitional Epithelium, Hyperplasia	1 (2%)		2 (4%)	1 (2%)

\*\*\* END OF REPORT \*\*\*